Chemotherapy

Rubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 8, 2021
Rubius, Spleen, SITC, AML, Cancer immunology, PD-L1, Cancer, Manuscript, G&A, RCT, Therapy, Autoimmunity, Anal cancer, CRO, Clinical trial, R, Food and Drug Administration, Antigen presentation, Initiate, Disease, U.S. FDA, Food, Blood, Society, Investment, NK, Pembrolizumab, HPV, Report, Research, Tumor microenvironment, Red Cell, Company, Annual general meeting, Environment, GLOBE, Degenerative disease, Interleukin 15, RED, Nasdaq, Patient, FDA, El Rubius, Chemotherapy, IND, Pharmaceutical industry, Vaccine, Medical imaging, Medical device, Lithium

CAMBRIDGE Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ (RCT) for the treatment of cancer and autoimmune diseases, today reported third quarter 2021 financial results and provided a business update.

Key Points: 
  • The Company thanks her for her contributions to Rubius and wishes her the best in the next chapter of her career.
  • The Company plans to present comprehensive results by the end of 2021 or during the first quarter of 2022.
  • General and administrative (G&A) expenses were flat at $12.0 million during the third quarter of 2021, as compared to the third quarter of 2020.
  • These increases were offset by a decrease in stock-based compensation expense of $1.1 million, following the vesting of large awards early in the third quarter of 2021.

GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates

Retrieved on: 
Monday, September 6, 2021
Clinical medicine, Medicine, Cancer treatments, Antineoplastic drugs, Immunology, Biotechnology, Antibody-drug conjugate, Immune checkpoint, Monoclonal antibody therapy, Biopharmaceutical, Chemotherapy, Immune system

(hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007.

Key Points: 
  • (hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007.
  • In recent years, immunotherapeutic antibody drugs targeting PD-1 and PD-L1 (representing immune checkpoint inhibitors) have revolutionized cancer therapy.
  • Linker stability is extremely important in the field of antibody immune agonist conjugates.
  • GeneQuntum focuses on the development of differentiated innovation products through in-house research and development and diversified external research and development cooperation.

HOPA Oncology Pharmacists Provide Chemotherapy Resources to Improve Patient Understanding and Outcomes

Retrieved on: 
Saturday, September 4, 2021
Health sciences, Health, Oncology, Medicinal chemistry, Pharmacy, Symbols, Pharmacist, Oncology Nursing Society, Oncology nursing

Oncology pharmacists are encouraged to use the education sheets in discussions with those undergoing cancer treatment and their caregivers.

Key Points: 
  • Oncology pharmacists are encouraged to use the education sheets in discussions with those undergoing cancer treatment and their caregivers.
  • The website is a joint effort dedicated to being forward-thinking and providing thorough education resources to improve treatment outcomes.
  • Oncology professionals and caregivers can download several IVE sheets from the site's library, which will continue to be updated by the collaborative.
  • The Hematology/Oncology Pharmacy Association (HOPA) supports hematology/oncology pharmacy professionals and promotes the role of the pharmacist in collaborative cancer care.

Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition

Retrieved on: 
Wednesday, August 25, 2021
PD, Company, University of Bonn, Lymphatic system, University, Chemotherapy, Competent authority, Lenalidomide, Congress, TAP, Cancer, Myelodysplastic syndrome, Ethics committee, Pharmacokinetics, Azacitidine, Knowledge, Research, CMO, Drug discovery, AML, Food, Competence, Doctor of Philosophy, Therapy, Virtual, WSE, Warsaw Stock Exchange, MDS, ODD, Senior, CTA, Clinical trial, CDK8, Ethics, Safety, Risk, Leukemia, Patient, Saskatchewan River Sturgeon Management Board, Acute myeloid leukemia, FDA, Leukemia & Lymphoma Society, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

The CTA submission process has already been initiated in Spain as well, aiming to start enrollment in Q4 2021.

Key Points: 
  • The CTA submission process has already been initiated in Spain as well, aiming to start enrollment in Q4 2021.
  • The subsequent Phase II part will include specific tumor indications, enrolled in distinct study cohorts.
  • During the CMO transition period, Prof. Axel Glasmacher, M.D., Ryvu Supervisory Board Member since 2019, will provide additional support for the company on a consulting basis.
  • The first-in-human Phase I study with RVU120 (SEL120), in relapsed or refractory AML or high-risk MDS, is enrolling patients at 5 investigational sites in the US.

SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, August 4, 2021
Health sciences, Health, Chemical compounds, Breakthrough therapy, Amides, Chemotherapy, Imidazoles, Nirogacestat, Clinical trial

The Company expects to complete enrollment of the trial in the second half of 2021.

Key Points: 
  • The Company expects to complete enrollment of the trial in the second half of 2021.
  • In June 2021, SpringWorks entered into a collaboration to conduct a Phase 1/2 clinical trial evaluating mirdametinib in children and young adults with low-grade glioma.
  • SpringWorks also expects that two additional collaborator-sponsored trials will initiate enrollment in the second half of 2021, as previously disclosed: nirogacestat + Pfizers elranatamab and nirogacestat + Seagen's SEA-BCMA.
  • Net Loss Attributable to Common Stockholders: SpringWorks reported net loss of $47.0 million, or $0.97 per share, for the second quarter of 2021.

iOnctura Boosts Management Team With Appointment of David Seeberger as VP Finance

Retrieved on: 
Wednesday, August 4, 2021
Oncology, Antineoplastic drugs, Cancer treatments, Health, Chemotherapy, Occupational safety and health, Branches of biology, Tumor microenvironment

iOnctura SA is a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface.

Key Points: 
  • iOnctura SA is a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface.
  • iOncturas best-in-class drug development programs combine immune-mediated and direct anti-tumor activity to deliver molecules with superior clinical efficacy and safety in oncology.
  • iOncturas second program, IOA-289, is an oral small molecule that inhibits the cross-talk between the tumor and its stroma and is in a Phase 1 clinical study.
  • iOnctura is backed by blue chip investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund.

Dignitana signs distributor B&Co Group to support Benelux Growth

Retrieved on: 
Thursday, July 29, 2021
Organ systems, Medicine, Clinical medicine, Human hair, Hair diseases, Hair loss, Chemotherapy, Hypothermia cap, Geerts

STOCKHOLM, July 29, 2021 /PRNewswire/ -- Dignitana , world leader in scalp cooling innovation, has signed with leading distributor B&Co Group to drive growth in the Benelux region.

Key Points: 
  • STOCKHOLM, July 29, 2021 /PRNewswire/ -- Dignitana , world leader in scalp cooling innovation, has signed with leading distributor B&Co Group to drive growth in the Benelux region.
  • The agreement kicks off with the sale of two DigniCap devices which are used by cancer centers to minimize hair loss from chemotherapy.
  • "Innovation is a key component of our business, and in that regard, we align well with Dignitana," said Bob Geerts, CEO and Founder of B&Co Group.
  • "The B&Co Group are experts in selling cutting edge medical devices and are known for their commitment to after-sales service and support," said William Cronin, Dignitana CEO.

Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results

Retrieved on: 
Wednesday, July 28, 2021
Medical specialties, Clinical medicine, Medicine, Hepatology, Cancer treatments, Cancer, Oncology, Delcath Systems, Percutaneous hepatic perfusion, Interventional oncology, Liver cancer, Chemotherapy

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021.

Key Points: 
  • NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021.
  • To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
  • The call will also be available over the Internet and accessible at:
    Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
  • The companys proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Panbela Schedules Conference Call on August 11, 2021, to Report 2021 Second Quarter Financial Results

Retrieved on: 
Wednesday, July 28, 2021
Health sciences, Health, Clinical research, Medicine, Design of experiments, Drug discovery, Pharmaceutical industry, Clinical trial, Chemotherapy, Randomized controlled trial

In data evaluated from clinical studies to date, SBP-101 has not shown exacerbation of bone marrow suppression or peripheral neuropathy, which can be chemotherapy-related adverse events.

Key Points: 
  • In data evaluated from clinical studies to date, SBP-101 has not shown exacerbation of bone marrow suppression or peripheral neuropathy, which can be chemotherapy-related adverse events.
  • The safety data and PMI profile observed in the current Panbela sponsored clinical trial generally provides support for continued evaluation of SBP-101 in a randomized clinical trial.
  • Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs.
  • Our actual results and financial condition may differ materially and adversely from the forward-looking statements.

Oncocyte to Report Second Quarter 2021 Financial Results on Tuesday, August 10

Retrieved on: 
Tuesday, July 27, 2021
Clinical medicine, Medicine, Cancer, Cancer treatments, Adjuvant therapy, Adjuvants, Analgesics, Health effects of tobacco, Chemotherapy, Lung cancer

The Company will host a conference call on Tuesday, August 10, 2021, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.

Key Points: 
  • The Company will host a conference call on Tuesday, August 10, 2021, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.
  • To access the live webcast, go to the investor relations section on the Companys website, or by clicking here: http://public.viavid.com/index.php?id=145975 .
  • The Companys tests are designed to help provide clarity and confidence to physicians and their patients at every stage of care.
  • DetermaRx identifies early-stage lung cancer patients who are at high risk for cancer recurrence and predicts benefit from adjuvant chemotherapy.